<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04375696</url>
  </required_header>
  <id_info>
    <org_study_id>IT-1501202</org_study_id>
    <nct_id>NCT04375696</nct_id>
  </id_info>
  <brief_title>Randomized Double Blind Placebo Controlled Clinical Trial to Evaluate Obese and Overweight Subjects</brief_title>
  <acronym>POSO</acronym>
  <official_title>Randomized Double Blind Placebo Controlled Clinical Study to Evaluate the Effect on Weight of a Medical Device With Polyglucosamine L 112 in a Group of Overweight and Obese Subjects: POSO Study (Polyglucosamine and Overweight)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Certmedica International GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Certmedica International GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effect on weight loss in a group of subjects
      suffering from overweight and mild obesity (BMI between 25 and 32 Kg/m2) and with weight &gt; 75
      Kg/m2 being administered with a 3 g/day polyglucosamine dosage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to evaluate the effect on weight loss in a group of
      subjects suffering from overweight and mild obesity (BMI between 25 and 32 Kg/m2) and with
      weight &gt; 75 Kg/m2 being administered with a 3 g/day polyglucosamine dosage.

      The secondary objectives of the study are:

        -  to evaluate the effect of supplementation on blood triglyceride levels

        -  to evaluate the effect of supplementation on blood levels of Total Cholesterol (CT),
           LDL, and HDL

        -  to evaluate the effect of supplementation on glucose, insulin, insulin resistance
           assessed by calculating the Homeostatic metabolic assessment (HOMA)

        -  to evaluate the effect of supplementation on liver enzymes (transaminases) and renal
           function (creatinine)

        -  to evaluate the effect of supplementation on BMI (Body Mass Index)

        -  to evaluate the effect of supplementation on the abdominal circumference

        -  to evaluate the effect of supplementation on body composition evaluated by dual X-ray
           densitometer (DXA)

        -  to evaluate the effect of supplementation on the serum levels of reactive oxygen species

        -  to evaluate the effect of supplementation on serum antioxidant capacity
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 24, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight Loss</measure>
    <time_frame>3-month treatment</time_frame>
    <description>To evaluate the weight loss with 3 g/die administration of polyglucosamine (PG)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>3-month treatment</time_frame>
    <description>To evaluate the effect of PG administration on triglycerides plasma levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>3-month treatment</time_frame>
    <description>To evaluate the effect of PG administration on total cholesterol plasma levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA</measure>
    <time_frame>3-month treatment</time_frame>
    <description>To evaluate the effect of PG administration on glucose, insulin, insulin resistance (measured through Homeostatic Metabolic Assessment - HOMA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic Enzymes - Renal Functionality</measure>
    <time_frame>3-month treatment</time_frame>
    <description>To evaluate the effect of PG administration on transaminases and creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>3-month treatment</time_frame>
    <description>To evaluate the effect of PG administration on BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal Circumference</measure>
    <time_frame>3-month treatment</time_frame>
    <description>To evaluate the effect of PG administration on the abdominal circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DXA</measure>
    <time_frame>3-month treatment</time_frame>
    <description>To evaluate the effect of PG administration on corporeal composition by means of DXA (Dual energy X-ray Absorptiometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ROS</measure>
    <time_frame>3-month treatment</time_frame>
    <description>To evaluate the effect of PG administration on ROS (Reactive Oxygen Species) serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antioxidant Serum Capacity</measure>
    <time_frame>3-month treatment</time_frame>
    <description>To evaluate the effect of PG administration on serum antioxidant capacity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 subjects of both sexes suffering from overweight and mild obesity BMI 25-32 and weigh in &gt; 75 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>60 subjects of both sexes suffering from overweight and mild obesity BMI 25-32 and weigh in &gt; 75 kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyglucosamine L112</intervention_name>
    <description>Polyglucosamine; Ascorbic Acid; Tartaric Acid</description>
    <arm_group_label>Product</arm_group_label>
    <other_name>Formoline L112</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dicalcium Phosphate; Microcrystalline Cellulose; Iron Oxide (yellow, brown, and black); Magnesium Stearate; Silicon Dioxide</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  Age between 18-65

          -  Both sexes - mandatory adequate contraceptive method for women in fertility age

          -  BMI between 25-32 kg/m2 and weigh in &gt; 75 kg, with no previous diet-therapy attempts
             with at least a 5% weight loss in the last year

          -  No 3 kg weight fluctuation in the last 3 months

          -  Beck Depression Inventory (BDI) score &lt; 20

          -  Binge Eating Scale (BES) score &lt; 27

        Exclusion Criteria:

          -  Shellfish allergy or to any other ingredient in the product

          -  Previous diet-therapy attempts with at least a 5% weight loss in the last year

          -  3 kg weight fluctuation in the last 3 months

          -  Presumed or confirmed pregnancy

          -  No contraceptive method for women in fertility age

          -  Cardiopathies, nephropathies, hepatopathies, bronchopneumopathies, hemopathies
             dermopathies clinically significant chronic degenerative CNS (Central Nervous System)
             diseases

          -  Active peptic ulcer, ulcerative colitis, Crohn disease, celiac disease, inflammatory
             bowel disease

          -  Alcoholism

          -  Epilepsy

          -  Past or current malignancies

          -  Intellectual disability

          -  Significant motor disability

          -  Drug abuse

          -  Autoimmune diseases

          -  Symptomatic cholelithiasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariangela Rondanelli, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pavia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda di Servizi alla Persona Istituzioni Assistenziali Riunite di Pavia</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 30, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polyglucosamine</keyword>
  <keyword>Formoline L112</keyword>
  <keyword>Medical Device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

